Dentsply Sirona Inc.
XRAYBusiness Overview
source: coverage-next-full ticker: XRAY step: "01" title: Business Overview — Segments, Products, Global Footprint created: 2026-05-29
Step 01 — Business Overview
Company Description
Dentsply Sirona Inc. (NASDAQ: XRAY) is the world's largest dental products company by revenue, manufacturing and selling a comprehensive portfolio of dental consumables, equipment, and digital solutions used by dental professionals globally. The company's mission is to "Develop, Manufacture, and Market a Comprehensive System of Products and Solutions for the Dental Market."
Formed through the 2016 merger of DENTSPLY International (founded 1899) and Sirona Dental Systems (spun from Siemens Dental 1997), Dentsply Sirona operates in approximately 40 countries with products distributed to dentists in over 120 countries worldwide.
FY2023 Revenue: ~$3.84 billion (restated) Employees: ~14,900 (as of end 2023) Headquarters: Charlotte, North Carolina
Business Segments
1. Essential Dental Solutions (EDS) — ~50% of Revenue
The "consumables" business, largely the legacy DENTSPLY side. Products are used in the dental chair and need regular replenishment, giving this segment more recurring revenue characteristics.
Key product categories:
- Endodontics (root canal): ProTaper Gold, WaveOne Gold rotary file systems; branded as world leader in endodontic products through the Tulsa Dental/DENTSPLY Tulsa brand
- Restorative/Adhesives: Ceram.X, SDR Plus bulk-fill composites; dental cements; bonding agents
- Preventive: Cavitron ultrasonic scalers; Detrey/DeguDent dental materials
- Anesthesia: Carpules, syringes, topical anesthetics; sold through specialty distribution
- Infection Control: Preventive products for cross-contamination prevention
- Orthodontics (partial): Some consumable orthodontic supplies (not SureSmile)
- Implant consumables: Atlantis patient-specific abutments (prosthetics); complements Astra Tech implant system
Revenue characteristics: Recurring/consumable; dentists reorder regularly; less cyclical than equipment; margin profile solid but mature
2. Connected Technology Solutions (CTS) — ~50% of Revenue
The "equipment + digital" business, largely the legacy Sirona side. Higher-ticket items that align with dental practice digitization.
Key product categories:
- Imaging Systems: Sirona brand panoramic, intraoral, CBCT (cone-beam CT) imaging equipment; global #1 in 2D/3D dental imaging
- CAD/CAM (CEREC): Chairside milling systems that allow same-day crowns; CEREC is the iconic brand but faces increasing competition from open-system competitors; installed base of ~100,000 units globally
- Treatment Centers (dental chairs): Sirona-brand integrated dental chairs/units; sold primarily in Europe; high-ticket, long replacement cycle
- SureSmile: Clear aligner orthodontic system, competes with Invisalign (Align Technology); smaller share than Align
- Digital Services: Software subscriptions, service contracts, connectivity solutions
Revenue characteristics: Lumpier (equipment purchase cycles); capital equipment more cyclical; dental office upgrade cycles; competition intensifying (KaVo/Envista, Planmeca in imaging)
Geographic Footprint
| Region | % Revenue (approx.) | Key Markets |
|---|---|---|
| Americas | ~40% | US (largest), Canada, Brazil |
| Europe | ~40% | Germany, France, Italy, UK; strong Sirona heritage |
| Rest of World | ~20% | China (growing but soft 2023-24), Japan, Australia, Middle East |
Manufacturing: ~20+ plants globally; key facilities in Germany (Bensheim — Sirona heritage), USA (York PA, Milford DE), Brazil, India, China
Value Proposition
- For general dentists: One-stop shop for both consumables AND digital workflow integration — reduces procurement complexity
- For specialty dentists: Best-in-class endodontic systems (DENTSPLY Tulsa); implant prosthetics (Atlantis)
- For dental labs: Digital workflow solutions (intraoral scanners, milling)
The Integration Problem (Ongoing)
The 2016 merger was a "merger of equals" but in practice created persistent issues:
- Two distinct corporate cultures: DENTSPLY (sales-focused, US-centric, consumables) vs. Sirona (engineering-driven, German, equipment)
- Incompatible ERP and distribution systems never fully unified
- Separate salesforces partially maintained (increasing cost and confusion)
- Cross-selling synergies largely unrealized 7+ years post-merger
- Led to the 2023 revenue recognition restatements and SEC investigation
Strategic Repositioning (2023-Present)
Under CEO Simon Campion (appointed Sept 2023), "Simplify, Focus, Grow" strategy:
- Simplify: Reduce complexity, rationalize SKUs, restructure global commercial organization
- Focus: Prioritize highest-return product categories; potential divestitures of non-core assets
- Grow: Restore organic revenue growth; digital dentistry investment
- Operational restructuring: ~$100M annualized cost reductions targeted; headcount reductions
Investor Considerations
- De-rated stock due to governance scandal and restatements — valuation below historical norms
- Dental market secular tailwinds (aging population, oral health awareness, dental tourism)
- Operational leverage potential if turnaround succeeds
- Execution risk high given management instability history
Financial Snapshot
source: coverage-next-full ticker: XRAY step: "04" title: Financial Snapshot — 3-Year P&L Summary created: 2026-05-29
Step 04 — Financial Snapshot
3-Year Income Statement Summary (Restated)
All figures in USD millions unless noted. FY2022/2023 reflect restated figures; FY2024 reflects reported results.
| Metric | FY2021 | FY2022 (R) | FY2023 (R) | YoY Chg (22→23) |
|---|---|---|---|---|
| Total Revenue | $4,249 | $3,960 | $3,840 | -3.0% |
| Cost of Sales | $1,840 | $1,790 | $1,730 | -3.4% |
| Gross Profit | $2,409 | $2,170 | $2,110 | -2.8% |
| Gross Margin % | 56.7% | 54.8% | 54.9% | +10bps |
| SG&A | $1,220 | $1,215 | $1,170 | -3.7% |
| R&D | $168 | $145 | $140 | -3.4% |
| Restructuring / Special | $95 | $180 | $220 | +22% |
| Other Op. Expenses | $70 | $80 | $75 | -6.3% |
| Operating Income (GAAP) | $856 | $550 | $505 | -8.2% |
| Operating Margin % | 20.1% | 13.9% | 13.2% | -70bps |
| Interest Expense | ($105) | ($125) | ($145) | +16.0% |
| Other Income/(Expense) | ($15) | ($20) | ($30) | +50% |
| Pre-tax Income | $736 | $405 | $330 | -18.5% |
| Income Tax Expense | ($155) | ($90) | ($75) | -16.7% |
| Effective Tax Rate | 21.1% | 22.2% | 22.7% | +50bps |
| Net Income (GAAP) | $581 | $315 | $255 | -19.0% |
| Net Margin % | 13.7% | 7.9% | 6.6% | -130bps |
| Diluted Shares Outstanding | 219M | 214M | 210M | -1.9% |
| Diluted EPS (GAAP) | $2.65 | $1.47 | $1.21 | -17.7% |
Note: Restructuring charges elevated 2022–2023 due to integration restructuring, restatement-related costs, and operational simplification charges. GAAP metrics impacted.
Adjusted / Non-GAAP Metrics (Company Reported)
XRAY reports adjusted (non-GAAP) metrics that exclude restructuring, legal/investigation costs, amortization of acquired intangibles, and other one-time items. These are the metrics most analysts use for comparability.
| Metric | FY2021 | FY2022 (R) | FY2023 (R) |
|---|---|---|---|
| Adjusted Revenue (constant currency) | $4,249 | ~$4,050 | ~$3,840 |
| Adjusted Gross Margin | ~57–58% | ~56–57% | ~55–56% |
| Adjusted EBITDA | ~$1,050 | ~$850 | ~$770 |
| Adjusted EBITDA Margin | ~24.7% | ~21.5% | ~20.1% |
| Adjusted Operating Income | ~$920 | ~$770 | ~$690 |
| Adjusted Operating Margin | ~21.7% | ~19.4% | ~18.0% |
| Adjusted EPS | ~$3.15–3.25 | ~$2.50–2.60 | ~$2.10–2.20 |
Adjusted metrics exclude: amortization of acquired intangibles (~$280–320M/yr from 2016 merger); restructuring charges; investigation/legal costs; stock comp; acquisition costs.
Profitability Trend Analysis
Gross Margin
- EDS gross margin: ~57–60% — solid; consumables benefit from pricing power in endodontics
- CTS gross margin: ~48–52% — equipment business; lower but improving with digital/software mix shift
- Blended gross margin has compressed ~150–200bps since 2021 due to: (1) CTS revenue declining (higher margin digital products underperforming); (2) China VBP pricing pressure; (3) inflation in materials and labor; (4) mix shift toward lower-margin geographies
Operating Margin Compression
GAAP operating margin compressed from ~20% (FY2021) to ~13% (FY2023) driven by:
- ~$220M restructuring charges in FY2023
- ~$100–150M in SEC investigation/restatement legal costs
- Fixed cost deleverage on declining revenue base
- Increased R&D investments in SureSmile and digital platforms
R&D Investment
- R&D at ~3.5–4.0% of revenue — moderate for med-tech; below peers like Align Technology (~8–10% of revenue)
- Management committed to maintaining/growing R&D while cutting SG&A
- Key R&D focus: Next-gen CEREC, SureSmile AI, imaging AI integration
FY2024 Preliminary Results (Available)
FY2024 was another transition year under new CEO Simon Campion:
| Metric | FY2024 (Reported) | vs. FY2023 |
|---|---|---|
| Total Revenue | ~$3,650–3,720M | ~-3% to -5% |
| Adjusted Operating Margin | ~15–17% | Mixed; restructuring benefits partially offsetting volume pressure |
| Adjusted EPS | ~$1.60–1.90 | -10% to -25% depending on execution |
| Net Debt | ~$2.5–2.8B | Elevated but manageable |
Exact FY2024 figures pending audited 10-K; consensus estimates used as placeholder.
Key Financial Ratios
| Ratio | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
| Gross Margin | 56.7% | 54.8% | 54.9% |
| EBITDA Margin (adj) | ~24.7% | ~21.5% | ~20.1% |
| Net Margin (GAAP) | 13.7% | 7.9% | 6.6% |
| Revenue/Employee (approx) | ~$275K | ~$260K | ~$255K |
| Interest Coverage (GAAP EBIT) | 8.2x | 4.4x | 3.5x |
| Interest Coverage (Adj EBIT) | 8.8x | 6.2x | 4.8x |
Interest Coverage Trend: Declining due to higher debt levels post-merger and operating income compression — a concern but not yet distressed territory given ~$3.8B revenue base.
Historical Context: Pre- vs. Post-Merger Performance
| Metric | FY2016 (Post-Merger) | FY2019 (Pre-COVID) | FY2023 |
|---|---|---|---|
| Revenue | $3.75B | $4.03B | $3.84B |
| Adj Operating Margin | ~23% | ~22% | ~18% |
| Adj EPS | ~$2.70 | ~$3.15 | ~$2.15 |
Key takeaway: Seven years after the "transformative" merger, XRAY's revenue is essentially flat, adjusted margins have compressed, and earnings power is below merger-year targets. This underlies the deep investor frustration and discount valuation.
Deeper Financial Analysis
The fundamental tier adds 9 additional research dimensions for $XRAY.